Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABIO ARCA biopharma		$384.99	$1.56 ▼ $4.49	$34.82M	0.91	607,995 shs	290,800 shs
ALTS ALT5 Sigma	$5.96 -9.7%	$8.03	$1.55 ▼ $10.95	$132.94M	2.17	3.14 million shs	29.45 million shs
GNLX Genelux	$3.19 -2.7%	$3.13	$1.93 ▼ $5.89	$123.90M	-0.32	134,124 shs	78,690 shs
IKT Inhibikase Therapeutics	$1.75 +15.9%	$1.81	$1.12 ▼ $4.20	$130.10M	0.9	196,334 shs	167,813 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABIO ARCA biopharma	0.00%	0.00%	0.00%	0.00%	-99.41%
ALTS ALT5 Sigma	-26.42%	-3.08%	-16.24%	-0.30%	+235.03%
GNLX Genelux	+4.13%	-6.55%	-4.37%	+32.26%	+53.99%
IKT Inhibikase Therapeutics	+5.59%	-5.63%	-18.38%	-32.29%	+17.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALTS ALT5 Sigma	0.1266 of 5 stars	0.0	1.0	0.0	0.0	3.3	0.0	0.0
GNLX Genelux	1.6517 of 5 stars	3.6	1.0	0.0	0.0	3.5	0.0	0.0
IKT Inhibikase Therapeutics	1.9189 of 5 stars	3.3	3.0	0.0	0.0	1.1	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABIO ARCA biopharma	0.00	N/A	N/A	N/A
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
GNLX Genelux	3.20	Buy	$17.75	456.43% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	271.43% Upside

Current Analyst Ratings Breakdown

Latest ABIO, ALTS, IKT, and GNLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/23/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	$2.25 per share	N/A
ALTS ALT5 Sigma	$12.53M	9.58	N/A	N/A	$0.49 per share	12.16
GNLX Genelux	$10K	12,048.63	N/A	N/A	$0.63 per share	5.06
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABIO ARCA biopharma	-$5.34M	-$0.42	N/A	N/A	N/A	N/A	-20.18%	-19.51%	N/A
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-38.58%	-113.79%	-8.96%	N/A
GNLX Genelux	-$29.87M	-$0.86	N/A	N/A	N/A	N/A	-107.47%	-83.14%	8/13/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A

Latest ABIO, ALTS, IKT, and GNLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	GNLX Genelux	-$0.22	-$0.20	+$0.02	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	N/A
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABIO ARCA biopharma	N/A	26.61	26.61
ALTS ALT5 Sigma	1.26	0.83	0.83
GNLX Genelux	N/A	4.18	4.67
IKT Inhibikase Therapeutics	N/A	0.85	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABIO ARCA biopharma	56.44%
ALTS ALT5 Sigma	6.27%
GNLX Genelux	37.33%
IKT Inhibikase Therapeutics	3.81%

Insider Ownership

Company	Insider Ownership
ABIO ARCA biopharma	30.90%
ALTS ALT5 Sigma	4.90%
GNLX Genelux	8.80%
IKT Inhibikase Therapeutics	7.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABIO ARCA biopharma	6	14.51 million	10.02 million	Optionable
ALTS ALT5 Sigma	170	20.14 million	19.16 million	N/A
GNLX Genelux	10	37.77 million	34.45 million	Not Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable

ABIO, ALTS, IKT, and GNLX Headlines

Recent News About These Companies

Reviewing Genocea Biosciences (NASDAQ:GNCAQ) & Inhibikase Therapeutics (NYSE:IKT)

August 2, 2025 | americanbankingnews.com

Inhibikase Therapeutics (NYSE:IKT) Shares Down 6.6% - Should You Sell?

July 25, 2025 | marketbeat.com

IKT Inhibikase Therapeutics, Inc. - Seeking Alpha

July 3, 2025 | seekingalpha.com

Inhibikase Therapeutics shareholders elect directors and approve equity plan changes

July 2, 2025 | investing.com

Inhibikase Therapeutics Insiders Placed Bullish Bets Worth US$2.70m

June 30, 2025 | finance.yahoo.com

Inhibikase Therapeutics Reports Q1 2025 Financial Results

May 22, 2025 | tipranks.com

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025 | finance.yahoo.com

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025 | globenewswire.com

Former Inhibikase leader launches new biotech for midstage Parkinson’s asset

May 12, 2025 | fiercebiotech.comF

Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 6.22%

May 9, 2025 | aaii.comA

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

May 5, 2025 | prnewswire.com

Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH

May 2, 2025 | seekingalpha.com

Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 5.30%

April 17, 2025 | aaii.comA

Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market

April 16, 2025 | nasdaq.com

Inhibikase Therapeutics Advances PAH Treatment with New Leadership

April 14, 2025 | tipranks.com

Inhibikase Therapeutics announces appointment of McIntyre as CFO

April 14, 2025 | markets.businessinsider.com

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

April 14, 2025 | globenewswire.com

Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 14.13%

April 8, 2025 | aaii.comA

Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses

April 4, 2025 | finance.yahoo.com

Inhibikase Therapeutics (IKT) Receives a Hold from H.C. Wainwright

March 29, 2025 | markets.businessinsider.com

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

March 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABIO, ALTS, IKT, and GNLX Company Descriptions

ARCA biopharma NASDAQ:ABIO

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

ALT5 Sigma NASDAQ:ALTS

$5.96 -0.64 (-9.70%)

Closing price 04:00 PM Eastern

Extended Trading

$6.10 +0.15 (+2.43%)

As of 07:59 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Genelux NASDAQ:GNLX

$3.19 -0.09 (-2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$3.21 +0.02 (+0.63%)

As of 06:36 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Inhibikase Therapeutics NYSE:IKT

$1.75 +0.24 (+15.89%)

Closing price 04:00 PM Eastern

Extended Trading

$1.75 +0.00 (+0.06%)

As of 05:00 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time